Rxsight vs Neogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Rxsight Inc (RXST)

Q3 20266 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

July 20266 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

Latest6 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

Neogen Corporation (NEOG)

Q3 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

August 202624 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.

Latest24 Jul – 7 Oct 2026

▲3▼1

Neogen's growth bets meet an FDA safety blow

Q4 beat and strong FY27 guidance Neogen's fiscal fourth-quarter revenue of $225.3 million beat expectations, with core growth accelerating to 4.3% and adjusted EBITDA up 12%. It guided fiscal 2027 revenue to $880–885 million and EBITDA to $180–182 million, and repaid $20 million of debt. A stronger profit outlook lifts the stock.
The earnings beat and guidance are the core reason the stock jumped and set the period's direction.
R&D boost and Petrifilm brought in-house Neogen plans to raise fiscal 2027 R&D spending about 50% and move Petrifilm manufacturing in-house, with the first sellable output starting November 2026 and at least two new product launches a year. Doing its own manufacturing can cut costs and speed new products, supporting future profit.
This is a concrete new investment plan that shapes Neogen's growth and margins beyond the quarter.
FDA warning letters over contaminated horse product The FDA issued warning letters after fungal contamination was found in Neogen's veterinary product HYCOAT, linked to severe joint infections in nearly 100 horses and at least 20 deaths. Shares fell 5.4%. This raises regulatory, legal and reputational risk that can weigh on the stock.
It is the main negative force this period and a real counterweight to the upbeat earnings news.
Guidance raised again above consensus Neogen lifted fiscal year revenue guidance to $885–890 million, above its earlier range and the $883.2 million consensus, sending shares up 11% before the market opened. The raise signals management sees demand holding up, which supports the stock.
The fresh guidance increase is the newest positive catalyst and confirms the growth trend.